Clinical Trial Update: Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating belantamab mafodotin plus standard of care in newly diagnosed multiple myeloma. The trial is currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING